Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. on November 13, 2018. The filing serves to announce the Company's financial results for the quarter ended September 30, 2018. The report references a press release furnished as Exhibit 99.1 containing the detailed results.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended September 30, 2018.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The Company explicitly states it does not assume any obligation to update the information in the future. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the press release attached as Exhibit 99.1.
- Confirm the Company's name is Imprimis Pharmaceuticals, Inc. (Note: The request metadata listed "Harrow, Inc.", but the filing text clearly identifies Imprimis Pharmaceuticals, Inc.).
- Review the full text of the press release for any forward-looking statements or operational updates not summarized in this 8-K.